News

Avadel Pharmaceuticals Unveils Groundbreaking Insights on LUMRYZ

Avadel Pharmaceuticals Unveils Groundbreaking Insights on LUMRYZ

Avadel Pharmaceuticals Showcases LUMRYZ™ at World Sleep 2025

Avadel Pharmaceuticals plc (NASDAQ: AVDL), a biopharmaceutical company committed to innovating treatments that change lives, announced an exciting presentation at World Sleep 2025. The event, taking place in Singapore, will feature the company showcasing vital research on LUMRYZ™, a once-nightly treatment for narcolepsy, encompassing one oral presentation and 16 poster presentations.

Dr. Gerard J. Meskill, CEO of Tricoastal Narcolepsy and Sleep Disorders Center, expressed enthusiasm over LUMRYZ’s unique once-nightly dosing, offering patients a hassle-free alternative to traditional treatments. This method alleviates the stress of waking at night for administration while ensuring that patients receive the therapeutic benefits throughout the entire night. The REFRESH study’s findings demonstrate significant improvements for those switching from a twice-nightly oxybate regimen, as well as for new patients.

Highlights from the REFRESH Study

The REFRESH study has provided meaningful insights that will be discussed at the upcoming conference. Key findings indicated that participants showed remarkable enhancements in their Epworth Sleepiness Scale (ESS) scores, dropping to the normal range, indicating reduced excessive daytime sleepiness (EDS). Furthermore, there was a notable decrease in symptoms measured by the Narcolepsy Severity Scale (NSS) from moderate to mild severity, reflecting a vast improvement in overall well-being among participants.

The data also revealed that a substantial majority of participants experienced positive outcomes after four months of treatment. Specifically, around 70% of switch participants and 90% of naïve participants reported improved conditions on standardized global scales. This transformation indicates the potential of LUMRYZ to significantly enhance the daily lives of those dealing with narcolepsy.

Comorbidities and Further Insights

A secondary analysis conducted at Duke University highlighted the common comorbidities faced by narcolepsy patients. The study compared data from nearly 1,700 narcolepsy patients with matched controls, revealing higher occurrences of psychiatric disorders, chronic pain, and sleep disturbances among those with narcolepsy. These insights stress the necessity of improved treatment options that address not just narcolepsy symptoms but associated challenges as well.

Jennifer Gudeman, Pharm.D. and Senior Vice President of Medical and Clinical Affairs at Avadel, remarked on the remarkable benefits of LUMRYZ demonstrated in research outcomes. She emphasized the effectiveness of LUMRYZ for both naïve patients and those switching from other oxybates, reinforcing its role in addressing complex narcolepsy symptoms.

Presentation Schedule at World Sleep 2025

The oral presentation scheduled for September 9 will focus on comparing the performance of LUMRYZ against standard treatments for daytime sleepiness among narcolepsy patients. Attendees can glean insights into how this innovative therapy aligns with broader treatment goals targeting reduced night-time interruptions.

Posters will cover diverse topics, including the impacts of once-nightly sodium oxybate on other sleep disorder metrics, providing a holistic view of the treatment's effectiveness. Presentations will include:

  • Effects of Once-Nightly Sodium Oxybate on Apnea-Hypopnea Index
  • Assessing Usability For Patients with Narcolepsy
  • Comorbidities in Narcolepsy Patients: Insights from Patient Data

About LUMRYZ and Its Impact

LUMRYZ stands out as a pioneering extended-release sodium oxybate, approved for treating EDS and cataplexy in individuals with narcolepsy. The innovative formulation ensures that patients receive the necessary dosage in a singular administration at bedtime, making it a convenient option for both adult and pediatric patients aged seven and above.

With its FDA approvals, LUMRYZ secured seven years of Orphan Drug Exclusivity. Its introduction into the market has been supported by extensive clinical trial data that attests to its superior efficacy compared to traditional therapies. This accomplishment signifies a critical advancement in narcolepsy treatment, underscoring LUMRYZ’s potential to transform patient care.

Avadel’s deep commitment is not just to bring LUMRYZ to market but to ensure that this revolutionary treatment becomes accessible to those in need, ultimately aiming to enhance the quality of life for many.

Frequently Asked Questions

What is LUMRYZ and how does it work?

LUMRYZ is an extended-release medication aimed at treating narcolepsy's symptoms through a once-nightly dose, ensuring effective management without night-time interruptions.

What were the main findings from the REFRESH study?

Participants in the REFRESH study saw significant improvements in symptoms of excessive daytime sleepiness and overall narcolepsy severity after switching to LUMRYZ.

How is LUMRYZ administered?

LUMRYZ is taken as a single oral dose at bedtime, allowing patients to manage their symptoms with ease and convenience.

Who is eligible for LUMRYZ treatment?

LUMRYZ is approved for patients with narcolepsy aged seven years and older and is effective for both new patients and those switching from other oxybate medications.

Where can I find more information about Avadel Pharmaceuticals?

For additional information, visit Avadel Pharmaceuticals' official website at www.avadel.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 77

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 113

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
Teciem’s New CFO Puts Financial Discipline Behind Growth

Updated Category News Views 87

A finance chief moving continents is not decorative corporate wallpaper. Teciem’s decision to appoint Jesús Rueda Molins as chief financial officer says the company wants its next growth chapter run with more than product ambition and executive slogans. It wants somebody holding the purse strings who already knows the machinery, the customers and the people making the...

Continue Reading
Mile High Labs Moves CBD Isolate Into FDA DMF Pathway

Updated Category News Views 76

A Quiet Filing With Real Commercial Weight Cannabis headlines usually arrive wearing a clown suit; this one showed up with paperwork. Mile High Labs says it filed Type II Drug Master File No. 044151 with the U.S. Food and Drug Administration for a 98% CBD isolate on October 2, 2026. That is not a product approval, not permission to market a CBD drug, and certainly not a...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 67

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 144

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 122

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 63

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading

Top 5 Most Recently Viewed Articles

Nokia Corporation Reports Managerial Transaction Details

Updated Category News Views 170

Nokia Corporation’s Managerial Transaction Insights Nokia Corporation has been making headlines recently as it showcases the ongoing engagement of its management in company affairs. An important transaction notification concerning Nishant Batra, a senior manager at Nokia, has been released, highlighting the movement of shares within the company. Transaction Overview...

Continue Reading
RBI Urges Banks to Limit Short Selling as Rupee Dips

Updated Category News Views 121

RBI's Call to Support the Rupee Amidst Market Challenges The Reserve Bank of India (RBI) has recently taken proactive measures to address the vulnerabilities of the Indian rupee, which has been hovering close to unprecedented low levels. This action follows a period in which market fluctuations have raised concerns among financial circles, particularly regarding the...

Continue Reading
Workhorse Group's E-GEN Platform Achieves Major Milestone

Updated Category News Views 260

Revolutionizing Commercial Transportation with E-GEN Milestone Workhorse Group Inc., renowned for its pioneering electric vehicle solutions, achieved an incredible feat with its E-GEN vehicles recently surpassing a remarkable 10 million cumulative miles. This significant milestone not only validates the platform’s durability but also showcases its reliability in...

Continue Reading
Investors Urged to Act Ahead of Starbucks Class Action Deadline

Updated Category News Views 231

Important Deadline for Starbucks Corporation Investors In light of recent developments, investors who purchased securities of Starbucks Corporation (NASDAQ: SBUX) are being encouraged to take action before an important deadline. Rosen Law Firm, a well-respected global investor rights law firm, has issued reminders for these investors. They are informing those who bought...

Continue Reading
Effective Strategies to Enhance Your Credit Before Holidays

Updated Category News Views 78

Essential Strategies for Boosting Your Credit Score TomoCredit, a dedicated platform aiding immigrants and underserved communities in accessing crucial credit without relying on credit scores, has developed a practical 5-week plan to help consumers enhance their credit before the holiday shopping frenzy. This guide aims to empower individuals to take control of their...

Continue Reading